Is Impact of Statin Therapy on All-Cause Mortality Different in HIV-Infected Individuals Compared to General Population? Results from the FHDH-ANRS CO4 Cohort.

摘要: Background The effect of statins on all-cause mortality in the general population has been estimated as 0.86 (95%CI 0.79-0.94) for primary prevention. Reported values HIV-infected individuals have discordant. We assessed impact statin-based prevention among individuals. Methods Patients were selected controls from a multicentre nested case-control study risk myocardial infarction. Patients with prior cardiovascular or cerebrovascular disorders not eligible. Potential confounders, including variables that associated either statin use and/or death occurrence and evaluated within last 3 months to inclusion study. Using an intention continue approach, multiple imputation missing data, Cox’s proportional hazard models propensity based weighting, 7-year was evaluated. Results Among 1,776 individuals, 138 (8%) users. During median follow-up 53 months, 76 deaths occurred, 6 Statin users had more factors lower CD4 T cell nadir than non-users. In univariable analysis, rate higher (11% vs 7%, HR 1.22, 95%CI 0.53-2.82). The confounders accounted age, HIV transmission group, current count, haemoglobin level, body mass index, smoking status, anti-HCV antibodies positivity, HBs antigen diabetes hypertension. Cox multivariable model ratio 0.34-2.19) it 0.83 0.51-1.35) using inverse probability treatment weights. Conclusion The appears similar population.